EQEquillium, Inc.

Nasdaq equilliumbio.com


$ 1.69 $ -0.10 (-5.52 %)    

Friday, 26-Apr-2024 15:58:44 EDT
QQQ $ 431.01 $ 6.55 (1.54 %)
DIA $ 382.27 $ 1.39 (0.36 %)
SPY $ 508.26 $ 4.77 (0.95 %)
TLT $ 88.26 $ 0.46 (0.52 %)
GLD $ 216.60 $ 0.70 (0.32 %)
$ 1.71
$ 1.70
$ 0.00 x 0
$ 0.00 x 0
$ 1.69 - $ 1.70
$ 0.45 - $ 3.25
80,229
na
59.38M
$ 0.83
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-25-2024 12-31-2023 10-K
2 11-08-2023 09-30-2023 10-Q
3 08-09-2023 06-30-2023 10-Q
4 05-11-2023 03-31-2023 10-Q
5 03-23-2023 12-31-2022 10-K
6 11-14-2022 09-30-2022 10-Q
7 08-15-2022 06-30-2022 10-Q
8 05-12-2022 03-31-2022 10-Q
9 03-23-2022 12-31-2021 10-K
10 11-10-2021 09-30-2021 10-Q
11 08-10-2021 06-30-2021 10-Q
12 05-13-2021 03-31-2021 10-Q
13 03-24-2021 12-31-2020 10-K
14 11-10-2020 09-30-2020 10-Q
15 08-12-2020 06-30-2020 10-Q
16 05-13-2020 03-31-2020 10-Q
17 03-26-2020 12-31-2019 10-K
18 11-12-2019 09-30-2019 10-Q
19 08-12-2019 06-30-2019 10-Q
20 05-13-2019 03-31-2019 10-Q
21 03-27-2019 12-31-2018 10-K
22 11-15-2018 09-30-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-maintains-buy-on-equillium-raises-price-target-to-5

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Equillium (NASDAQ:EQ) with a Buy and raises the price target fr...

 why-westport-fuel-systems-shares-are-trading-lower-by-around-10-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of Westport Fuel Systems Inc. (NASDAQ: WPRT) fell sharply during Tuesday’s session after posting a wider-than-expected ...

 equillium-q4-earnings-insights
Equillium: Q4 Earnings Insights
03/25/2024 21:35:06

 equillium-q4-2023-gaap-eps-007-beats-017-estimate-sales-9200m-beat-6425m-estimate

Equillium (NASDAQ:EQ) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.17) by 58...

 cognizant-technology-solutions-to-rally-over-13-here-are-10-top-analyst-forecasts-for-tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

 hc-wainwright--co-maintains-buy-on-equillium-lowers-price-target-to-4

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Equillium (NASDAQ:EQ) with a Buy and lowers the price target fr...

 equillium-announces-update-on-multi-cytokine-inhibitors-eq101--eq102-in-development-for-alopecia-areata-and-celiac-disease

EQ101 Phase 2 study in alopecia areata is fully enrolled with topline data expected in Q2 2024EQ302, an orally delivered multi-...

 hc-wainwright--co-maintains-buy-on-equillium-lowers-price-target-to-45

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Equillium (NASDAQ:EQ) with a Buy and lowers the price target fr...

 equillium-presents-data-from-phase-1b-equalise-study-at-the-2023-annual-meeting-of-the-american-college-of-rheumatology

Itolizumab continues to show clinically meaningful response in highly proteinuric subjectsAt Week 28, 73% of subjects achieved ...

 equillium-q3-eps-011-beats-021-estimate-sales-887m-beat-800m-estimate

Equillium (NASDAQ:EQ) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.21) by 47...

 equillium-announces-data-from-phase-1b-equalise-study-was-presented-at-2023-annual-meeting-of-the-american-society-of-nephrology

Itolizumab continues to show clinically meaningful response in highly proteinuric subjectsAt Week 28, 73% of subjects achieved ...

 equillium-announces-preclinical-data-from-new-orally-deliverable-multi-cytokine-inhibitor-in-presentation-at-the-18th-annual-peptide-therapeutics-symposium

Equillium Inc. (NASDAQ:EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe aut...

 cantor-fitzgerald-reiterates-overweight-on-equillium-maintains-28-price-target

Cantor Fitzgerald analyst Emma Nealon reiterates Equillium (NASDAQ:EQ) with a Overweight and maintains $2.8 price target.

 hc-wainwright--co-reiterates-buy-on-equillium-maintains-55-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Equillium (NASDAQ:EQ) with a Buy and maintains $5.5 price target.

 equillium-q2-eps-010-beats-021-estimate-sales-912m-beat-800m-estimate

Equillium (NASDAQ:EQ) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.21) by 52...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION